within Pharmacolibrary.Drugs.ATC.C;

model C10AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.00185,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Gemfibrozil is a lipid-regulating drug classified as a fibric acid derivative, used primarily for the treatment of hyperlipidemia and hypertriglyceridemia. It is indicated to reduce cardiovascular risk in dyslipidemic patients, particularly those with high triglycerides. Gemfibrozil is still approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Lennernäs, H (2003). Clinical pharmacokinetics of atorvastatin. <i>Clinical pharmacokinetics</i> 42(13) 1141–1160. DOI:<a href=\"https://doi.org/10.2165/00003088-200342130-00005\">10.2165/00003088-200342130-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14531725/\">https://pubmed.ncbi.nlm.nih.gov/14531725</a></p></li><li><p>Kosoglou, T, Statkevich, P, Johnson-Levonas, AO, Paolini, JF, Bergman, AJ, &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00002\">10.2165/00003088-200544050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871634/\">https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Yang, SJ, Kim, BJ, Mo, L, &amp; Han, HK (2016). Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. <i>Biopharmaceutics &amp; drug disposition</i> 37(5) 245–251. DOI:<a href=\"https://doi.org/10.1002/bdd.2001\">10.1002/bdd.2001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26663350/\">https://pubmed.ncbi.nlm.nih.gov/26663350</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AB04;
